Your browser is no longer supported. Please, upgrade your browser.
Settings
FPRX Five Prime Therapeutics, Inc. daily Stock Chart
FPRX [NASD]
Five Prime Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.20 Insider Own2.30% Shs Outstand38.66M Perf Week-12.15%
Market Cap525.39M Forward P/E- EPS next Y-4.36 Insider Trans0.00% Shs Float33.79M Perf Month-22.16%
Income-126.90M PEG- EPS next Q-1.21 Inst Own94.20% Short Float7.97% Perf Quarter-27.52%
Sales61.60M P/S8.53 EPS this Y-120.60% Inst Trans0.40% Short Ratio8.10 Perf Half Y-28.81%
Book/sh9.79 P/B1.39 EPS next Y-8.90% ROA-33.10% Target Price34.57 Perf Year-51.04%
Cash/sh9.13 P/C1.49 EPS next 5Y- ROE-40.60% 52W Range13.41 - 48.87 Perf YTD-38.00%
Dividend- P/FCF- EPS past 5Y25.30% ROI-57.70% 52W High-71.86% Beta3.33
Dividend %- Quick Ratio12.00 Sales past 5Y31.70% Gross Margin- 52W Low2.54% ATR0.74
Employees216 Current Ratio12.00 Sales Q/Q-2.60% Oper. Margin- RSI (14)30.08 Volatility7.05% 4.95%
OptionableYes Debt/Eq0.00 EPS Q/Q37.50% Profit Margin- Rel Volume0.62 Prev Close13.59
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume332.12K Price13.75
Recom2.10 SMA20-9.90% SMA50-15.82% SMA200-31.03% Volume201,928 Change1.18%
Jun-28-18Initiated Raymond James Mkt Perform
Jun-15-18Initiated JP Morgan Neutral $19
May-18-18Initiated Wedbush Neutral
Nov-06-17Reiterated RBC Capital Mkts Outperform $41 → $50
Sep-15-17Initiated RBC Capital Mkts Outperform $41
Mar-02-17Initiated Instinet Buy $94
Oct-25-16Initiated Citigroup Buy
Jan-21-16Initiated Credit Suisse Outperform
Dec-04-15Resumed Wells Fargo Outperform
Oct-19-15Reiterated Oppenheimer Outperform $45 → $48
Jul-31-15Initiated Citigroup Buy
May-15-15Initiated Oppenheimer Outperform $45
Aug-11-18 05:29PM  Edited Transcript of FPRX earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 07:20PM  Five Prime Therapeutics (FPRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:14PM  Five Prime Therapeutics: 2Q Earnings Snapshot Associated Press
04:05PM  Five Prime Therapeutics Announces Second Quarter 2018 Financial Results Business Wire
02:30PM  Five Prime Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 08:00AM  Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Jul-26-18 04:05PM  Five Prime Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 8 Business Wire
Jul-11-18 07:35AM  Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks ACCESSWIRE
Jun-21-18 06:00AM  Five Prime Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-11-18 04:05PM  Five Prime Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference Business Wire
Jun-07-18 11:05AM  5 Top-Ranked High-Beta Stocks to Play the Roaring Market InvestorPlace
Jun-03-18 09:00AM  Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster at the 2018 ASCO Annual Meeting Business Wire
May-31-18 04:05PM  Five Prime Therapeutics to Present at Jefferies 2018 Global Healthcare Conference Business Wire
May-30-18 04:05PM  Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates Business Wire
May-29-18 04:05PM  Five Prime Therapeutics Walks to End Pancreatic Cancer at PurpleStride San Francisco 2018 Business Wire
May-15-18 04:05PM  Five Prime Therapeutics Appoints Bryan Irving, Ph.D., as Chief Scientific Officer Business Wire
May-10-18 01:11AM  Edited Transcript of FPRX earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 06:09PM  Five Prime Therapeutics: 1Q Earnings Snapshot Associated Press -5.70%
04:05PM  Five Prime Therapeutics Announces First Quarter 2018 Financial Results Business Wire
Apr-25-18 03:01PM  Five Prime to Present at 2018 ASCO Annual Meeting Business Wire
Apr-24-18 04:05PM  Five Prime Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on May 8 Business Wire
Apr-15-18 02:50PM  Five Prime Presents on Novel B7-H4 Therapeutic Antibody at the 2018 AACR Annual Meeting Business Wire
Apr-03-18 02:07PM  Five Prime Therapeutics Inc (NASDAQ:FPRX): Poised For Long-Term Success? Simply Wall St.
07:00AM  Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics' Targeted Immuno-Oncology Drug Candidate Bemarituzumab PR Newswire
Mar-28-18 04:05PM  Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150 Business Wire -5.96%
Mar-27-18 04:05PM  Five Prime Therapeutics Announces Oral Presentation on FPA150 at the 2018 AACR Annual Meeting Business Wire
Mar-22-18 09:16AM  5 Stocks that Boast Superb Earnings Acceleration Zacks
Mar-19-18 09:00AM  Five Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery Platform Business Wire
Mar-15-18 07:02PM  With A -128.66% Earnings Drop, Is Five Prime Therapeutics Incs (NASDAQ:FPRX) A Concern? Simply Wall St. -11.23%
Mar-13-18 04:05PM  Five Prime Therapeutics Announces Executive Change Business Wire
Mar-06-18 04:05PM  Five Prime Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference Business Wire
Feb-28-18 06:11PM  Edited Transcript of FPRX earnings conference call or presentation 27-Feb-18 9:30pm GMT Thomson Reuters StreetEvents +14.42%
Feb-27-18 06:03PM  Five Prime Therapeutics posts 4Q loss Associated Press
04:05PM  Five Prime Announces Fourth Quarter and Full Year 2017 Financial Results Business Wire
12:20PM  Five Prime Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-18 06:00AM  A Six-Pack of Biotech Bets Investopedia
Feb-15-18 07:40AM  New Research Coverage Highlights Trevena, Five Prime Therapeutics, Endocyte, FireEye, CSRA, and Orchid Island Capital Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Feb-13-18 07:29PM  An Intrinsic Value Calculation For Five Prime Therapeutics Inc (NASDAQ:FPRX) Shows Its 42.22% Undervalued Simply Wall St.
04:05PM  Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27 GlobeNewswire
Feb-08-18 04:10PM  Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire -5.98%
Feb-01-18 11:02AM  High Growth Stocks To Invest In Simply Wall St.
Jan-29-18 04:05PM  Five Prime Therapeutics Announces Closing of Upsized Public Offering GlobeNewswire
Jan-25-18 04:05PM  Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone GlobeNewswire +6.80%
08:00AM  Five Prime Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire
Jan-23-18 04:01PM  Five Prime Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-08-18 08:30AM  Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time GlobeNewswire
Jan-03-18 04:05PM  Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
04:05PM  Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150 GlobeNewswire
Jan-02-18 04:05PM  Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer GlobeNewswire
08:07AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Jan-01-18 11:02AM  January Growth Stock Opportunities Simply Wall St.
Dec-26-17 11:32AM  ETFs with exposure to Five Prime Therapeutics, Inc. : December 26, 2017 Capital Cube
Dec-25-17 09:18AM  Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-19-17 04:05PM  Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development Collaboration GlobeNewswire
Dec-13-17 01:18PM  ETFs with exposure to Five Prime Therapeutics, Inc. : December 13, 2017 Capital Cube
Dec-04-17 04:05PM  Five Prime Therapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-30-17 08:07AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Nov-27-17 08:06AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Nov-21-17 08:07AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Nov-20-17 08:07AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Nov-17-17 08:05AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Nov-16-17 09:44AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Nov-15-17 08:06AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Nov-14-17 08:04AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Nov-13-17 04:07PM  Why This Biotech Still Gets Hit Despite Promising Cancer Data Investor's Business Daily -9.95%
Nov-10-17 12:30PM  Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting GlobeNewswire
08:14AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Nov-09-17 08:00AM  Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors Business Wire -8.77%
Nov-08-17 05:00PM  Why Five Prime Therapeutics Stock Is on the Rebound Today Motley Fool +17.71%
Nov-07-17 08:19PM  Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data Business Wire -40.90%
03:04PM  Have Investors Already Priced In Five Prime Therapeutics Incs (FPRX) Growth? Simply Wall St.
09:24AM  Sarepta Rises as FDA Clears Investigational Drug Application -- Biotech Movers TheStreet.com
09:24AM  Sarepta Rises After FDA Clears Investigational Drug Application -Biotech Movers TheStreet.com
08:00AM  Five Prime Therapeutics to Host Conference Call on November 11th to Review Cabiralizumab Phase 1a/1b Data to be Presented in Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting GlobeNewswire
Nov-06-17 10:46PM  Edited Transcript of FPRX earnings conference call or presentation 6-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
04:59PM  Five Prime Therapeutics posts 3Q loss Associated Press
04:05PM  Five Prime Announces Third Quarter 2017 Results and Provides Business Update GlobeNewswire
07:15AM  Five Prime Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-30-17 08:00AM  Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155 GlobeNewswire
Oct-23-17 04:05PM  Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018 GlobeNewswire
Oct-19-17 04:05PM  Five Prime Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 6 GlobeNewswire
Oct-18-17 04:05PM  Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Oct-17-17 09:43AM  ETFs with exposure to Five Prime Therapeutics, Inc. : October 17, 2017 Capital Cube
Oct-13-17 08:57AM  Five Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2% Zacks
Oct-11-17 04:15PM  Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting GlobeNewswire
Oct-06-17 10:51AM  ETFs with exposure to Five Prime Therapeutics, Inc. : October 6, 2017 Capital Cube
Oct-05-17 09:37AM  Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 Capital Cube
Sep-25-17 08:05AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Sep-21-17 09:00AM  Five Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology GlobeNewswire
Sep-11-17 01:30PM  Array BioPharma And Others Shine At The ESMO 2017 Congress Benzinga +8.04%
Sep-10-17 11:45AM  Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress GlobeNewswire
04:45AM  Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress GlobeNewswire
Sep-01-17 04:05PM  Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress GlobeNewswire
Aug-29-17 10:07PM  Five Prime Therapeutics, Inc. Value Analysis (NASDAQ:FPRX) : August 30, 2017 Capital Cube
04:05PM  Five Prime to Feature Two Oral Data Presentations at ESMO 2017 Congress GlobeNewswire
Aug-23-17 08:58AM  Five Prime Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FPRX-US : August 23, 2017 Capital Cube
Aug-17-17 04:05PM  Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research GlobeNewswire
Aug-14-17 08:05AM  See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc. Markit
Aug-12-17 08:16AM  Edited Transcript of FPRX earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-17 11:59PM  Five Prime Therapeutics posts 2Q loss Associated Press
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. Its product candidates also comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor IIb, which is in Phase I clinical trials to treat patients with gastric or gastroesophageal junction and bladder cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 as a monotherapy in various cancers. The company's FP-1039 is in Phase Ib clinical trials to treat patients with malignant pleural mesothelioma. Its preclinical product candidates include FPA150, a CD8 T cell checkpoint inhibitor antibody; FPA154, a tetravalent agonistic antibody that activates glucocorticoid-induced tumor necrosis factor receptor; and FPT155, a CD80-Fc fusion protein, which modulates signaling pathways. The company has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; collaboration agreement with Roche; and license agreements with bluebird bio, Inc., Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. Five Prime Therapeutics, Inc. was founded in 2001 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Knickerbocker Aron MarcPresident & CEOAug 15Option Exercise11.145005,570193,367Aug 16 01:18 PM
Knickerbocker Aron MarcPresident & CEOAug 13Option Exercise11.145005,570192,867Aug 14 03:18 PM
Knickerbocker Aron MarcPresident & CEOAug 08Option Exercise11.145005,570192,367Aug 08 07:49 PM
Knickerbocker Aron MarcPresident & CEOAug 07Option Exercise11.145005,570191,867Aug 08 07:49 PM
Knickerbocker Aron MarcChief Operating OfficerNov 29Option Exercise5.546,17534,210177,521Nov 30 07:19 PM
RINGO WILLIAM RDirectorNov 01Option Exercise11.656006,990600Nov 02 02:13 PM
RINGO WILLIAM RDirectorNov 01Sale45.3360027,1980Nov 02 02:13 PM
Knickerbocker Aron MarcChief Operating OfficerOct 12Option Exercise7.4211,05181,947171,346Oct 16 07:34 PM
RINGO WILLIAM RDirectorOct 02Option Exercise11.656006,990600Oct 03 07:08 PM
RINGO WILLIAM RDirectorOct 02Sale40.7860024,4680Oct 03 07:08 PM
RINGO WILLIAM RDirectorSep 29Option Exercise11.651,20013,9801,200Oct 03 07:08 PM
RINGO WILLIAM RDirectorSep 29Sale40.001,20048,0000Oct 03 07:08 PM
RINGO WILLIAM RDirectorSep 28Option Exercise11.652,00023,3002,000Oct 02 02:01 PM
RINGO WILLIAM RDirectorSep 28Sale38.002,00076,0000Oct 02 02:01 PM